Debiopharm International SA collaborates in EORTC trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Debiopharm International SA announced a collaboration in order to supply triptorelin pamoate 3.75 mg one-month formulation for patients suffering from salivary gland cancer participating in a clinical study sponsored by the European Organisation for Research and Treatment of Cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.

Login